<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName></PublisherName>
				<JournalTitle>Journal of Research in Pharmacy Practice</JournalTitle>
				<Issn></Issn>
				<Volume>4</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>A short review on structure and role of cyclic‑3’,5’‑adenosine monophosphate‑specific phosphodiesterase 4 as a treatment tool</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>175</FirstPage>
			<LastPage>181</LastPage>
			<ELocationID EIdType="pii">30235</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>.</FirstName>
					<LastName>Nahid Eskandari</LastName>
<Affiliation>Department of Immunology, 
Isfahan University of Medical 
Sciences, Isfahan, Iran
Applied Physiology Research 
Center, Isfahan University of 
Medical Sciences, Isfahan, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Omid Mirmosayyeb</LastName>
<Affiliation>Department of Immunology, 
Isfahan University of Medical 
Sciences, Isfahan, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Gazaleh Bordbari</LastName>
<Affiliation>Department of Immunology, 
Isfahan University of Medical 
Sciences, Isfahan, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Reza Bastan</LastName>
<Affiliation>Department of Human 
Vaccines, Razi Serum and 
Vaccine Research Institute, 
Karaj, Alborz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Zahra Yousefi</LastName>
<Affiliation>Department of Immunology, 
Isfahan University of Medical 
Sciences, Isfahan, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Alireza Andalib</LastName>
<Affiliation>Department of Immunology, 
Isfahan University of Medical 
Sciences, Isfahan, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2023</Year>
					<Month>03</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		<Abstract>Cyclic nucleotide phosphodiesterases (PDEs) are known as a super‑family of enzymes &lt;br /&gt;which catalyze the metabolism of the intracellular cyclic nucleotides, cyclic‑3’,5’‑adenosine &lt;br /&gt;monophosphate (cAMP), and cyclic‑3’,5’‑guanosine monophosphate that are expressed in &lt;br /&gt;a variety of cell types that can exert various functions based on their cells distribution. The &lt;br /&gt;PDE4 family has been the focus of vast research efforts over recent years because this family &lt;br /&gt;is considered as a prime target for therapeutic intervention in a number of inflammatory &lt;br /&gt;diseases such as asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis, &lt;br /&gt;and it should be used and researched by pharmacists. This is because the major isoform of &lt;br /&gt;PDE that regulates inflammatory cell activity is the cAMP‑specific PDE, PDE4. This review &lt;br /&gt;discusses the relationship between PDE4 and its inhibitor drugs based on structures, cells &lt;br /&gt;distribution, and pharmacological properties of PDE4 which can be informative for all &lt;br /&gt;pharmacy specialists.&lt;br /&gt;&lt;br /&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Cyclic‑3’,5’‑adenosine monophosphate</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">inhibitors</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">phosphodiesterase</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">  phosphodiesterase 4</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jrpp.mui.ac.ir/article_30235_24d26100b9d2097f0418ed14dd528b38.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName></PublisherName>
				<JournalTitle>Journal of Research in Pharmacy Practice</JournalTitle>
				<Issn></Issn>
				<Volume>4</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Nasal carriage of Methicillin- and Mupirocin-resistant S. aureus among health care workers in a tertiary care hospital</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>182</FirstPage>
			<LastPage>186</LastPage>
			<ELocationID EIdType="pii">30236</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>.</FirstName>
					<LastName>Loveleena Agarwal</LastName>
<Affiliation>Department of Microbiology, 
Mayo Institute of Medical 
Sciences, Barabanki, 
Uttar Pradesh, India</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Amit Kumar Singh</LastName>
<Affiliation>Department of Microbiology, 
Mayo Institute of Medical 
Sciences, Barabanki, 
Uttar Pradesh, India</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Chandrim Sengupta</LastName>
<Affiliation>Department of Microbiology, 
Mayo Institute of Medical 
Sciences, Barabanki, 
Uttar Pradesh, India</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Amitabh Agarwal</LastName>
<Affiliation>Department of Physiology, 
Mayo Institute of Medical 
Sciences, Barabanki, 
Uttar Pradesh, India</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2023</Year>
					<Month>03</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		<Abstract>Objective: Methicillin‑resistant Staphylococcus aureus (MRSA) ranks top among the &lt;br /&gt;nosocomial pathogens. Nasal formulation of mupirocin is found to eradicate MRSA from &lt;br /&gt;colonized individuals, but the emergence of resistant strains is a matter of concern.&lt;br /&gt;Methods: Nasal swabs were collected from 200 health care workers (HCWs) who were &lt;br /&gt;screened for MRSA. Kirby–Bauer disc diffusion method was used to perform antibiotic &lt;br /&gt;susceptibility test. MRSA detection was done using a cefoxitin 30 µg disc and interpreted &lt;br /&gt;according to the Clinical and Laboratory Standards Institute guidelines. Determination of &lt;br /&gt;mupirocin resistance was performed using Epsilometer test (E‑test).&lt;br /&gt;Findings: About 14% of HCWs showed nasal carriage of MRSA. Nursing orderlies were &lt;br /&gt;the predominant carriers. E‑test showed four mupirocin resistant isolates. The antibiogram &lt;br /&gt;of the MRSA isolates revealed the higher resistance to antibiotics as compared to &lt;br /&gt;methicillin‑sensitive Staphylococcus aureus. All the MRSA isolates were sensitive to linezolid.&lt;br /&gt;Conclusion: HCWs in our hospital showed high nasal carriage rate of MRSA, particularly &lt;br /&gt;the nursing orderlies which is statistically significant. It is advisable to detect mupirocin &lt;br /&gt;resistance among the isolates obtained from the HCWs so that in case of resistance, &lt;br /&gt;alternative treatment should be sought.&lt;br /&gt;&lt;br /&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">health care workers</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">methicillin‑resistant Staphylococcus aureus</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">  mupirocin-resistant S. aureus</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Nasal carriage</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jrpp.mui.ac.ir/article_30236_e9a0ddc40651a765e246e1f4b8c3d3c8.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName></PublisherName>
				<JournalTitle>Journal of Research in Pharmacy Practice</JournalTitle>
				<Issn></Issn>
				<Volume>4</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Comparison of the effects of intravenous premedication: Midazolam, Ketamine, and combination of both on reducing anxiety in pediatric patients before general anesthesia</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>187</FirstPage>
			<LastPage>192</LastPage>
			<ELocationID EIdType="pii">30237</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>.</FirstName>
					<LastName>Parvin Sajedi</LastName>
<Affiliation>Department of Anesthesia and 
Critical Care, Isfahan University 
of Medical Sciences, Isfahan, 
Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Bashir Habibi</LastName>
<Affiliation>Department of Anesthesia and 
Critical Care, Isfahan University 
of Medical Sciences, Isfahan, 
Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2023</Year>
					<Month>03</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		<Abstract>Objective: In some medical circumstances, pediatric patients may need premedication for &lt;br /&gt;transferring to the operating room. In these situations, using intravenous premedication &lt;br /&gt;is preferred. We assessed the efficacy and safety of intravenous midazolam, intravenous &lt;br /&gt;ketamine, and combination of both to reduce the anxiety and improve behavior in children &lt;br /&gt;undergoing general anesthesia.&lt;br /&gt;Methods: In a double‑blind randomized clinical trial, 90 pediatric patients aged 6 months &lt;br /&gt;to 6 years with American Society of Anesthesiologist grade I or II were enrolled. Before &lt;br /&gt;anesthesia, children were randomly divided into three groups to receive intravenous &lt;br /&gt;midazolam 0.1 mg/kg, or intravenous ketamine 1 mg/kg, or combination of half doses &lt;br /&gt;of both. Behavior types and sedation scores were recorded before premedication, after &lt;br /&gt;premedication, before anesthesia, and after anesthesia in the postanesthesia care unit. &lt;br /&gt;Anesthesia time, recovery duration, blood pressure, and heart rate were also recorded. For &lt;br /&gt;comparing distribution of behavior types and sedation scores among three groups, we used &lt;br /&gt;Kruskal–Wallis test, and for comparing mean and standard deviation of blood pressure and &lt;br /&gt;heart rates, we used analysis of variance.&lt;br /&gt;Findings: After premedication, children’s behavior was significantly better in the combination &lt;br /&gt;group (P &lt; 0.001). After anesthesia, behavior type was same among three groups (P = 0.421). &lt;br /&gt;Sedation scores among three groups were also different after premedication and the &lt;br /&gt;combination group was significantly more sedated than the other two groups (P &lt; 0.001).&lt;br /&gt;Conclusion: Combination of 0.05 mg/kg of intravenous midazolam and 0.5 mg/kg of &lt;br /&gt;intravenous ketamine as premedication produced more deep sedation and more desirable &lt;br /&gt;behavior in children compared with each midazolam 0.1 mg/kg or ketamine 1 mg/kg.&lt;br /&gt;&lt;br /&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Ketamine</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Midazolam</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Pediatric</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Premedication</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jrpp.mui.ac.ir/article_30237_965052c6a03942b536a3ff2d134d61c1.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName></PublisherName>
				<JournalTitle>Journal of Research in Pharmacy Practice</JournalTitle>
				<Issn></Issn>
				<Volume>4</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Serum Vitamin D levels at admission predict the length of intensive care unit stay but not in‑hospital mortality of critically ill surgical patients</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>193</FirstPage>
			<LastPage>198</LastPage>
			<ELocationID EIdType="pii">30238</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>.</FirstName>
					<LastName>Nafiseh Alizadeh</LastName>
<Affiliation>Department of Clinical 
Pharmacy, Tehran University of 
Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Hossein Khalili</LastName>
<Affiliation>Department of Clinical 
Pharmacy, Imam Khomeini 
Hospital, Tehran University of 
Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Mostafa Mohammadi</LastName>
<Affiliation>Department of Intensive Care 
Unit, Imam Khomeini Hospital, 
Tehran University of Medical 
Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Alireza Abdollahi</LastName>
<Affiliation>Department of Pathology, 
Imam Khomeini Hospital, 
Tehran University of Medical 
Sciences, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2023</Year>
					<Month>03</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		<Abstract>Objective: There is few data regarding the correlation between serum Vitamin D level &lt;br /&gt;and unfavorable intensive care unit (ICU) outcome in postsurgical patients. In this study, &lt;br /&gt;correlation between serum 25(OH)D level and length of ICU stay and in‑hospital mortality &lt;br /&gt;has been evaluated in critically ill surgical patients.&lt;br /&gt;Methods: Serum 25(OH)D has been evaluated in 70 surgical, critically ill patients. &lt;br /&gt;Demographic, laboratory, and clinical data of the patients were collected. Correlation between &lt;br /&gt;serum 25(OH) D level and duration of ICU stay and hospital mortality was evaluated using &lt;br /&gt;two‑factor analysis of covariance. Multivariable Cox‑regression analysis was used for adjusting &lt;br /&gt;the effect of season of blood sampling and type of surgery on the main variables. For all &lt;br /&gt;the analyses, P values less than or equal to 0.05 were considered as statistically significant.&lt;br /&gt;Findings: Serum 25(OH)D deficiency was identified in 52 (74.3%) of the patients. Patients &lt;br /&gt;with serum Vitamin D levels &lt; 30 ng/ml had longer length of ICU stay than those with &lt;br /&gt;serum Vitamin D levels ≥ 30 ng/ml (7.8 ± 5.1 vs. 4.05 ± 2.12 days, P = 0.003). Although &lt;br /&gt;hospital mortality was more common in Vitamin D deficient patients than sufficient ones &lt;br /&gt;(25% in deficient group versus 22.2% in sufficient group), there was no significant difference &lt;br /&gt;regarding hospital mortality rate between the groups.&lt;br /&gt;Conclusion: Statistically significant association was found between low 25(OH)D level &lt;br /&gt;and increased length of ICU stay in critically ill surgical patients. It could be explained by &lt;br /&gt;favorable effects of Vitamin D on immune system functions, reducing tissue dysfunction, and &lt;br /&gt;risk of organ failure and overall complications. However, there was no correlation between &lt;br /&gt;serum Vitamin D level and patients’ in‑hospital mortality. Further, well‑designed prospective &lt;br /&gt;clinical studies with adequate sample size are needed to evaluate correlation between serum &lt;br /&gt;Vitamin D level and mortality in critically ill patients.&lt;br /&gt;&lt;br /&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">critically ill patients</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">intensive care unit stay</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Mortality</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">surgical</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Vitamin D</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jrpp.mui.ac.ir/article_30238_b276f01d37dac0090b04042539a2aaab.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName></PublisherName>
				<JournalTitle>Journal of Research in Pharmacy Practice</JournalTitle>
				<Issn></Issn>
				<Volume>4</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>A news media analysis of economic sanction effects on access to medicine in Iran</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>199</FirstPage>
			<LastPage>205</LastPage>
			<ELocationID EIdType="pii">30239</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>.</FirstName>
					<LastName>Mehrnaz Kheirandish</LastName>
<Affiliation>Department of 
Pharmacoeconomics and 
Pharmaceutical Management, 
Tehran University of Medical 
Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Arash Rashidian</LastName>
<Affiliation>Department of Health 
Management and Economics, 
Tehran University of Medical 
Sciences, Tehran, Iran
Knowledge Utilization 
Research Center, Tehran 
University of Medical Sciences, 
Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Maryam Bigdeli</LastName>
<Affiliation>Alliance for Health Policy 
and Systems Research, World 
Health Organization, Geneva, 
Switzerland</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2023</Year>
					<Month>03</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		<Abstract>Objective: In the past decades economic sanctions have been used by different countries &lt;br /&gt;or international organizations in order to deprive target countries of some transactions. &lt;br /&gt;While the sanctions do not target health care systems or public health structures, they &lt;br /&gt;may, in fact, affect the availability of health care in target countries. In this study, we used &lt;br /&gt;media analysis to assess the impacts of recent sanctions imposed by the Central Bank of &lt;br /&gt;Iran in 2012 on access to medicines in Iran.&lt;br /&gt;Methods: We searched different sources of written news media including a database of &lt;br /&gt;nonspecialized weeklies and magazines, online news sources, web pages of daily newspapers &lt;br /&gt;and healthcare oriented weeklies from 2011 to 2013. We searched the sources using the &lt;br /&gt;general term “medicine” to reduce the chances of missing relevant items. The identified news &lt;br /&gt;media were read, and categorized under three groups of items announcing “shortage of &lt;br /&gt;medicines,” “medicines related issues” and “no shortage.” We conducted trend analyzes to &lt;br /&gt;see whether the news media related to access to medicines were affected by the economic &lt;br /&gt;sanctions.&lt;br /&gt;Findings: A total number of 371 relevant news media were collected. The number of news &lt;br /&gt;media related to medicines substantially increased in the study period: 30 (8%), 161 (43%) &lt;br /&gt;and 180 (49%) were published in 2011, 2012 and 2013, respectively. While 145 (39%) of &lt;br /&gt;media items referred to the shortage of medicines, 97 (26%) reported no shortage or &lt;br /&gt;alleviating of concerns.&lt;br /&gt;Conclusion: Media analysis suggests a clear increase in the number of news media reporting &lt;br /&gt;a shortage in Iran after the sanctions. In 2013, there were accompanying increases in the &lt;br /&gt;number of news media reporting alleviation of the shortages of medicines. Our analysis &lt;br /&gt;provides evidence of negative effects of the sanctions on access to medicines in Iran.&lt;br /&gt;&lt;br /&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Economic crisis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">economic sanction</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Health</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Medicine</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">news media</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jrpp.mui.ac.ir/article_30239_12f9ed7d561f5536e2316645dba28c66.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName></PublisherName>
				<JournalTitle>Journal of Research in Pharmacy Practice</JournalTitle>
				<Issn></Issn>
				<Volume>4</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>The pattern and risk factors associated with adverse drug reactions induced by Reteplase in patients with acute ST‑elevation myocardial infarction: The first report from Iranian population</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>206</FirstPage>
			<LastPage>211</LastPage>
			<ELocationID EIdType="pii">30240</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>.</FirstName>
					<LastName>Naser Aslanabadi</LastName>
<Affiliation>Cardiovascular Research 
Center, Tabriz University of 
Medical Sciences, Tabriz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Naser Safaie</LastName>
<Affiliation>Drug Applied Research Center, 
Tabriz University of Medical 
Sciences, Tabriz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Faezeh Shadfar</LastName>
<Affiliation>Cardiovascular Research 
Center, Tabriz University of 
Medical Sciences, Tabriz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Mohammad Reza Taban-Sadeghi</LastName>
<Affiliation>Cardiovascular Research 
Center, Tabriz University of 
Medical Sciences, Tabriz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Hossein Feizpour</LastName>
<Affiliation>Cardiovascular Research 
Center, Tabriz University of 
Medical Sciences, Tabriz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Simin Ozar Mashayekhi</LastName>
<Affiliation>Drug Applied Research Center, 
Tabriz University of Medical 
Sciences, Tabriz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Hadi Hamishehkar</LastName>
<Affiliation>Drug Applied Research Center, 
Tabriz University of Medical 
Sciences, Tabriz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Naser Khezerlou Aghdam</LastName>
<Affiliation>Cardiovascular Research 
Center, Tabriz University of 
Medical Sciences, Tabriz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Samaneh Dousti</LastName>
<Affiliation>Cardiovascular Research 
Center, Tabriz University of 
Medical Sciences, Tabriz, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Hossein Namdar</LastName>
<Affiliation>Cardiovascular Research 
Center, Tabriz University of 
Medical Sciences, Tabriz, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2023</Year>
					<Month>03</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		<Abstract>Objective: Acute myocardial infarction (AMI) is one of the main leading causes of mortality &lt;br /&gt;and morbidity. Reteplase is a fibrin‑specific thrombolytic which is used in the treatment &lt;br /&gt;of AMI. There is a limited number of studies reporting the postmarketing adverse drug &lt;br /&gt;reactions (ADRs) induced by reteplase. This study was aimed to examine the reteplase &lt;br /&gt;pattern of ADR and its associated risk factors in patients with acute ST‑elevation myocardial &lt;br /&gt;infarction.&lt;br /&gt;Methods: A cross‑sectional, prospective study in an 8‑month period was done at the &lt;br /&gt;University affiliated referral cardiovascular center. The Naranjo probability scale and World &lt;br /&gt;Health Organization criteria for severity of ADRs were used for assessing the ADRs. The &lt;br /&gt;linear regression and logistic regression tests were used to evaluate the correlation between &lt;br /&gt;ADRs and risk factors.&lt;br /&gt;Findings: The all 20 patients who received reteplase during the study period were entered. &lt;br /&gt;The majority of patients (n = 17) experienced at least one ADR. The results showed that &lt;br /&gt;the incidence of ADRs was mainly associated with gender and age, and the number of ADRs &lt;br /&gt;was associated with the history of diabetes and taking anti‑diabetic agents. The gender was &lt;br /&gt;the main predictor in the occurrence of ADRs (odds ratio: 32, 95% confidence interval: &lt;br /&gt;1.38–737.45; P = 0.030).&lt;br /&gt;Conclusion: The results showed that gender, age, diabetes mellitus, and using of anti‑diabetes &lt;br /&gt;medications are the risk factors associated with the incidence of ADRs by reteplase.&lt;br /&gt;&lt;br /&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Acute myocardial infarction</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Adverse drug reactions</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Reteplase</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jrpp.mui.ac.ir/article_30240_5ecc26b612316e2494011f9fcafa610f.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName></PublisherName>
				<JournalTitle>Journal of Research in Pharmacy Practice</JournalTitle>
				<Issn></Issn>
				<Volume>4</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Pediatric hospital admission due to adverse drug reactions: Report from a tertiary center</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>212</FirstPage>
			<LastPage>215</LastPage>
			<ELocationID EIdType="pii">30241</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>.</FirstName>
					<LastName>Kheirollah Gholami</LastName>
<Affiliation>Department of Clinical 
Pharmacy, Tehran University of 
Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Fatemeh Babaie</LastName>
<Affiliation>Department of Clinical 
Pharmacy, Tehran University of 
Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Gloria Shalviri</LastName>
<Affiliation>Iranian Adverse Drug Reaction 
Monitoring Center, Food and 
Drug Organization, Ministry of 
Health, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Mohammad Reza Javadi</LastName>
<Affiliation>Department of Clinical 
Pharmacy, Tehran University of 
Medical Sciences, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Toktam Faghihi</LastName>
<Affiliation>Department of Clinical 
Pharmacy, Tehran University of 
Medical Sciences, Tehran, Iran
Pediatrics Center of Excellence, 
Children&amp;#039;s Medical Center, 
Tehran University of Medical 
Sciences, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2023</Year>
					<Month>03</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		<Abstract>Objective: Adverse drug reactions (ADRs) are known as a cause of hospital admission. We &lt;br /&gt;have carried out a prospective study to characterize and assess the frequency, probability, &lt;br /&gt;preventability, and severity of ADRs, which lead to hospital admission in children.&lt;br /&gt;Methods: In a prospective observational study, a cohort of children admitted to a tertiary &lt;br /&gt;pediatric hospital was randomly screened to assess ADR as the cause of admission from June &lt;br /&gt;2014 to January 2015. ADRs causing admissions were detected based on patients’ records, &lt;br /&gt;interviewing their parents, and confirmation by medical team. The probability of the ADRs &lt;br /&gt;was assessed based on WHO criteria and Naranjo tool. The preventability assessment was &lt;br /&gt;performed using Schumock and Thornton questionnaire.&lt;br /&gt;Findings: Of the 658 evaluated emergency admissions, 27 were caused by an ADR giving &lt;br /&gt;an incidence of 4.1%. Among ADRs, 37.1% were estimated to be preventable. Antibiotics &lt;br /&gt;were the most common medication class which caused hospital admission.&lt;br /&gt;Conclusion: Pediatric pharmacotherapy still needs evidence‑based strategies to improve &lt;br /&gt;child care including education, monitoring, planning for medications after ADR occurrence, &lt;br /&gt;and implementing preventive measures when applicable.&lt;br /&gt;&lt;br /&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Adverse drug reaction</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Children</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Hospitalization</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Incidence</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jrpp.mui.ac.ir/article_30241_a0ac90988690d6ab675e7758a92d5828.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName></PublisherName>
				<JournalTitle>Journal of Research in Pharmacy Practice</JournalTitle>
				<Issn></Issn>
				<Volume>4</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Drug‑related problems in medical wards of Tikur Anbessa specialized hospital, Ethiopia</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>216</FirstPage>
			<LastPage>221</LastPage>
			<ELocationID EIdType="pii">30242</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>.</FirstName>
					<LastName>Mohammed Biset Ayalew</LastName>
<Affiliation>Department of Clinical 
Pharmacy, College of Medicine 
and Health Sciences, Gondar 
University, Gondar, Ethiopia</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Teshome Nedi Megersa</LastName>
<Affiliation>Department of Pharmacology 
and Clinical Pharmacy, College 
of Health Sciences, Addis 
Ababa University, Addis Ababa, 
Ethiopia</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Yewondwossen Taddese Mengistu</LastName>
<Affiliation>Department of Internal 
Medicine, College of Health 
Sciences, Addis Ababa 
University, Addis Ababa, 
Ethiopia</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2023</Year>
					<Month>03</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		<Abstract>Objective: This study was aimed to determine the prevalence of drug‑related &lt;br /&gt;problems (DRPs), identify the most common drugs, and drug classes involved in DRPs as &lt;br /&gt;well as associated factors with the occurrence of DRPs.&lt;br /&gt;Methods: A prospective cross‑sectional study was conducted on 225 patients admitted to &lt;br /&gt;medical wards of Tikur Anbessa Specialized Hospital, Addis Ababa from March to June 2014. Data &lt;br /&gt;regarding patient characteristics, medications, diagnosis, length of hospitalization, investigation, &lt;br /&gt;and laboratory results were collected using data abstraction forms through review of patients’ &lt;br /&gt;medical card and medication charts. Identified DRPs were recorded and classified using DRP &lt;br /&gt;registration forms. The possible intervention measures for the identified DRPs were proposed &lt;br /&gt;and communicated to either the physician or the patient. Data were entered into Epi Info &lt;br /&gt;7 and analyzed using SPSS version 21 (IBM Corp. Released 2012, Armonk, NY: IBM Corp).&lt;br /&gt;Findings: DRPs were found in 52% of study subjects. A drug‑drug interaction (48% of all DRPs) &lt;br /&gt;was the most common DRP followed by adverse drug reaction (23%). Anti‑infectives and &lt;br /&gt;gastrointestinal medicines were commonly involved in DRPs. Drugs with the highest drug &lt;br /&gt;risk ratio were gentamycin, warfarin, nifedipine, and cimetidine. The number of drugs taken &lt;br /&gt;by the patient per day is an important risk factor for DRPs.&lt;br /&gt;Conclusion: DRPs are common among medical ward patients. Polypharmacy has a significant &lt;br /&gt;association with the occurrence of DRP. Drugs such as gentamycin, warfarin, nifedipine, and &lt;br /&gt;cimetidine have the highest probability of causing DRP. So, patients who are taking either &lt;br /&gt;of these drugs or polypharmacy should be closely assessed for identification and timely &lt;br /&gt;correction of DRPs.&lt;br /&gt;&lt;br /&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Drug‑related problem</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">medical wards</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">polypharmacy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Tikur Anbessa  specialized hospital</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jrpp.mui.ac.ir/article_30242_9653a371e569e87de203013fe8ed79a4.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName></PublisherName>
				<JournalTitle>Journal of Research in Pharmacy Practice</JournalTitle>
				<Issn></Issn>
				<Volume>4</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Drug use evaluation of Meropenem at a tertiary care university hospital: A report from Northern Iran</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>222</FirstPage>
			<LastPage>225</LastPage>
			<ELocationID EIdType="pii">30243</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>.</FirstName>
					<LastName>Ebrahim Salehifar</LastName>
<Affiliation>Department of Clinical 
Pharmacy, Thalassemia Research 
Center, Mazandaran University 
of Medical Sciences, Sari, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Afshin Shiva</LastName>
<Affiliation>Department of Clinical 
Pharmacy, Urmia University of 
Medical Sciences, Urmia, Iran
Department of Clinical 
Pharmacy, Pharmaceutical 
Sciences Research Center, 
Mazandaran University of 
Medical Sciences, Sari, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Mona Moshayedi</LastName>
<Affiliation>Department of Clinical 
Pharmacy, Pharmaceutical 
Sciences Research Center, 
Mazandaran University of 
Medical Sciences, Sari, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Taravat Samiei Kashi</LastName>
<Affiliation>Student&amp;#039;s Research Committee, 
Faculty of Pharmacy, 
Mazandaran University of 
Medical Sciences, Sari, Iran</Affiliation>

</Author>
<Author>
					<FirstName>.</FirstName>
					<LastName>Aroona Chabra</LastName>
<Affiliation>Student&amp;#039;s Research Committee, 
Faculty of Pharmacy, 
Mazandaran University of 
Medical Sciences, Sari, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2023</Year>
					<Month>03</Month>
					<Day>28</Day>
				</PubDate>
			</History>
		<Abstract>Objective: The inappropriate use of antibiotics remains the primary factor in antimicrobial &lt;br /&gt;drug resistance. In this study, we evaluate the use of meropenem in surgical/medical wards &lt;br /&gt;of Imam Khomeini Tertiary Referral Hospital, Sari, Iran.&lt;br /&gt;Methods: This retrospective observational study was used to assess rational use of &lt;br /&gt;meropenem. The study was conducted by reviewing medical records of 100 admitted patients &lt;br /&gt;who received meropenem during March 2013 to January 2014.&lt;br /&gt;Findings: Meropenem was prescribed most frequently in Intensive Care Unit (22%), and &lt;br /&gt;pneumonia was the most common diagnosis(35%). The third‑generation cephalosporins were &lt;br /&gt;the most frequently prescribed antimicrobials after meropenem (53%). In 21% of the patients, &lt;br /&gt;imipenem was changed to meropenem. Most of the inappropriate uses were seen in terms &lt;br /&gt;of frequency of meropenem use (34%), followed by duration of meropenem therapy (28%).&lt;br /&gt;Conclusion: Comparing our study results has shown higher inappropriate use. It is necessary &lt;br /&gt;to take action to improve prescribing habit in order to reduce the unnecessary usage of &lt;br /&gt;antibiotic thus enhance rational antibiotic use.&lt;br /&gt;&lt;br /&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Antimicrobial resistance</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">appropriate drug use</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Drug use evaluation</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">  Meropenem</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jrpp.mui.ac.ir/article_30243_630571ee8e61fb9efaa9786a9de27353.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
